NCT01423240撤回3 期
A Randomized, 6-week, Double-blind, Placebo-controlled, Fixed-dose, Parallel Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 试验地点
- 27
- 主要终点
- MADRS
研究概览
简要总结
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.
- •Subject is 18 to 75 years of age, inclusive. Subject has MDD (diagnosed by DSM-IV-TR, and confirmed by the Structured Clinical Interview for DSM-IV Disorders - Clinical Trial version [SCID-CT]).
- •Subject is currently experiencing a major depressive episode (diagnosed by DSM-IV-TR; at least 2 weeks in duration) AND two or three of the following manic symptoms occurring on most days over at least the last 2 weeks (confirmed by the SCID-CT modified for Study D1050305):
- •Elevated, expansive mood
- •Inflated self-esteem or grandiosity
- •More talkative than usual or pressure to keep talking
- •Flight of ideas or subjective experience that thoughts are racing
- •Increase in energy or goal-directed activity (either socially, at work or school, or sexually)
- •Increased or excessive involvement in activities that have a high potential for painful consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)
- •Decreased need for sleep (feeling rested despite sleeping less than usual; to be contrasted from insomnia) Subject has a rater-administered Montgomery-Asberg Depression Rating Scale (MADRS) total score of ≥ 26 at screening and both a rater-administered and self-rated (administered by computer) MADRS total score ≥ 26 at baseline.
排除标准
- •Subject has Axis I or Axis II diagnosis other than MDD that has been the primary focus of treatment within the 3 months prior to screening Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the C-SSRS (at time of evaluation) at screening or baseline visit.
- •Subject has attempted suicide within the past 3 months. Subject has a lifetime history of any bipolar I manic or mixed manic episode. Subject has any abnormal laboratory parameter at screening that indicates a clinically significant medical condition as determined by the Investigator.
研究组 & 干预措施
Lurasidone 20 mg
Experimental
干预措施: Lurasidone 20 mg (Drug)
Lurasidone 60 mg
Experimental
干预措施: Lurasidone 60 mg (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
MADRS
时间窗: 6 weeks
Mean change from baseline in MADRS total score after 6 weeks of treatment
次要结局
- CGI-S(6 weeks)
研究者
研究点 (27)
Loading locations...
相似试验
已完成
3 期
Major Depressive Disorder (MDD) With Mixed Features - Flexible DoseMajor Depressive Disorder With Mixed FeaturesNCT01421134Sumitomo Pharma America, Inc.211
已完成
3 期
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I DepressionBipolar DepressionNCT01284517Sumitomo Pharma America, Inc.356
已完成
3 期
Major Depressive Disorder With Mixed Features - ExtensionMajor Depressive DisorderNCT01423253Sumitomo Pharma America, Inc.48
已完成
3 期
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)Bipolar DepressionNCT00868452Sumitomo Pharma America, Inc.348
已完成
3 期
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic AgentsSchizophreniaSchizoaffective DisorderNCT01143077Sumitomo Pharma America, Inc.244